Sei Investments Co. boosted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 12.7% during the second quarter, Holdings Channel reports. The fund owned 110,465 shares of the medical research company’s stock after buying an additional 12,424 shares during the period. Sei Investments Co.’s holdings in Charles River Laboratories International were worth $11,174,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Cambridge Advisors Inc. purchased a new stake in shares of Charles River Laboratories International during the second quarter worth about $202,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Charles River Laboratories International during the second quarter worth about $217,000. MAI Capital Management purchased a new stake in shares of Charles River Laboratories International during the first quarter worth about $224,000. Massmutual Trust Co. FSB ADV raised its stake in shares of Charles River Laboratories International by 5.0% in the first quarter. Massmutual Trust Co. FSB ADV now owns 2,739 shares of the medical research company’s stock worth $246,000 after buying an additional 130 shares during the last quarter. Finally, Charter Trust Co. raised its stake in shares of Charles River Laboratories International by 4.6% in the first quarter. Charter Trust Co. now owns 3,030 shares of the medical research company’s stock worth $272,000 after buying an additional 134 shares during the last quarter. 95.81% of the stock is currently owned by institutional investors.

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) opened at 98.36 on Thursday. The stock’s 50 day moving average price is $99.95 and its 200-day moving average price is $91.50. The stock has a market cap of $4.69 billion, a price-to-earnings ratio of 28.79 and a beta of 1.02. Charles River Laboratories International, Inc. has a 52-week low of $67.20 and a 52-week high of $102.32.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a net margin of 9.28% and a return on equity of 27.46%. The business had revenue of $469.13 million for the quarter, compared to the consensus estimate of $458.25 million. During the same quarter last year, the firm posted $1.20 EPS. The business’s revenue for the quarter was up 8.1% compared to the same quarter last year. On average, analysts predict that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current fiscal year.

Charles River Laboratories International declared that its Board of Directors has approved a share buyback plan on Wednesday, May 10th that allows the company to repurchase $150.00 million in outstanding shares. This repurchase authorization allows the medical research company to reacquire shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its stock is undervalued.

TRADEMARK VIOLATION NOTICE: “Charles River Laboratories International, Inc. (CRL) Shares Bought by Sei Investments Co.” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/charles-river-laboratories-international-inc-crl-shares-bought-by-sei-investments-co/1468690.html.

A number of brokerages have issued reports on CRL. Barclays PLC set a $90.00 target price on Charles River Laboratories International and gave the company a “hold” rating in a research report on Saturday, May 13th. Zacks Investment Research raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $111.00 target price on the stock in a research report on Wednesday, July 12th. Jefferies Group LLC reissued a “buy” rating and issued a $121.00 target price on shares of Charles River Laboratories International in a research report on Friday, June 30th. Credit Suisse Group reissued a “neutral” rating and issued a $95.00 target price (up previously from $89.00) on shares of Charles River Laboratories International in a research report on Tuesday, June 6th. Finally, BidaskClub raised Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, June 20th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the stock. Charles River Laboratories International currently has an average rating of “Hold” and an average target price of $97.06.

In other news, Chairman James C. Foster sold 9,516 shares of the firm’s stock in a transaction on Monday, July 10th. The shares were sold at an average price of $98.92, for a total value of $941,322.72. Following the transaction, the chairman now owns 361,171 shares of the company’s stock, valued at approximately $35,727,035.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director George Massaro sold 1,130 shares of the firm’s stock in a transaction on Friday, May 12th. The shares were sold at an average price of $88.30, for a total transaction of $99,779.00. Following the completion of the transaction, the director now directly owns 15,831 shares in the company, valued at approximately $1,397,877.30. The disclosure for this sale can be found here. In the last three months, insiders sold 80,499 shares of company stock worth $7,946,191. Insiders own 2.20% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.